You just read:

Updated Phase III Results Reinforce Safety and Efficacy of Praxbind® (idarucizumab) in Urgent Situations

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Nov 15, 2016, 12:56 ET